Source: Eur Respir J 2007; 29: 617-618



Rating:

Share or cite this content

Citations should be made in the following way:
Hiemstra P. S.. Antimicrobial peptides in the real world: implications for cystic fibrosis. Eur Respir J 2007; 29: 617-618

Member's Comments

No comment yet.

Related content which might interest you: Managing antimicrobial resistance in cystic fibrosis Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care Year: 2014 The role of antimicrobial peptides in cystic fibrosis in childhood. Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Biofilms and how to combat them: examples from cystic fibrosis Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Emerging pathogens in cystic fibrosis Source: International Congress 2019 – State of the art session: Paediatric respiratory diseases Year: 2019 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Newborn screening for cystic fibrosis: opportunities and remaining challenges Source: Eur Respir Monogr 2014; 64: 65-76 Year: 2014 Disease modifying genes: The cystic fibrosis lesson Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 What’s new in cystic fibrosis? Source: International Congress 2018 – Paediatric Year in Review Year: 2018 Molecular detection of complex microbial communities in sputa of patients with cystic fibrosis and non cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis Source: Eur Respir J, 50 (2) 1700763; 10.1183/13993003.00763-2017 Year: 2017 Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise? Source: Eur Respir J 2007; 29: 229-230 Year: 2007 Current concepts: host–pathogen interactions in cystic fibrosis airways disease Source: Eur Respir Rev 2014; 23: 320-332 Year: 2014 The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Host specificity of pseudomonas aeruginosa isolates from patients with cystic fibrosis and patients from different clinical backgrounds Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018